Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Chagas Disease Drug Discovery: Multiparametric Lead Optimization against Trypanosoma cruzi in Acylaminobenzothiazole Series.

Fleau C, Padilla A, Miguel-Siles J, Quesada-Campos MT, Saiz-Nicolas I, Cotillo I, Cantizani Perez J, Tarleton RL, Marco M, Courtemanche G.

J Med Chem. 2019 Nov 27;62(22):10362-10375. doi: 10.1021/acs.jmedchem.9b01429. Epub 2019 Nov 18.

PMID:
31657555
2.

Protozoan persister-like cells and drug treatment failure.

Barrett MP, Kyle DE, Sibley LD, Radke JB, Tarleton RL.

Nat Rev Microbiol. 2019 Oct;17(10):607-620. doi: 10.1038/s41579-019-0238-x. Epub 2019 Aug 23. Review.

PMID:
31444481
3.

Drug Discovery for Kinetoplastid Diseases: Future Directions.

Rao SPS, Barrett MP, Dranoff G, Faraday CJ, Gimpelewicz CR, Hailu A, Jones CL, Kelly JM, Lazdins-Helds JK, Mäser P, Mengel J, Mottram JC, Mowbray CE, Sacks DL, Scott P, Späth GF, Tarleton RL, Spector JM, Diagana TT.

ACS Infect Dis. 2019 Feb 8;5(2):152-157. doi: 10.1021/acsinfecdis.8b00298. Epub 2018 Dec 13.

4.

Highly competent, non-exhausted CD8+ T cells continue to tightly control pathogen load throughout chronic Trypanosoma cruzi infection.

Pack AD, Collins MH, Rosenberg CS, Tarleton RL.

PLoS Pathog. 2018 Nov 12;14(11):e1007410. doi: 10.1371/journal.ppat.1007410. eCollection 2018 Nov.

5.

Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes.

Albareda MC, Natale MA, De Rissio AM, Fernandez M, Serjan A, Alvarez MG, Cooley G, Shen H, Viotti R, Bua J, Castro Eiro MD, Nuñez M, Fichera LE, Lococo B, Scollo K, Tarleton RL, Laucella SA.

Front Immunol. 2018 Sep 13;9:1958. doi: 10.3389/fimmu.2018.01958. eCollection 2018.

6.

Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure.

Sánchez-Valdéz FJ, Padilla A, Wang W, Orr D, Tarleton RL.

Elife. 2018 Mar 26;7. pii: e34039. doi: 10.7554/eLife.34039.

7.

Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection.

Sanchez Alberti A, Bivona AE, Cerny N, Schulze K, Weißmann S, Ebensen T, Morales C, Padilla AM, Cazorla SI, Tarleton RL, Guzmán CA, Malchiodi EL.

NPJ Vaccines. 2017 Apr 10;2:9. doi: 10.1038/s41541-017-0010-z. eCollection 2017.

8.

Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins.

Soares Medeiros LC, South L, Peng D, Bustamante JM, Wang W, Bunkofske M, Perumal N, Sanchez-Valdez F, Tarleton RL.

MBio. 2017 Nov 7;8(6). pii: e01788-17. doi: 10.1128/mBio.01788-17.

9.

The Significance of Discordant Serology in Chagas Disease: Enhanced T-Cell Immunity to Trypanosoma cruzi in Serodiscordant Subjects.

Castro Eiro MD, Alvarez MG, Cooley G, Viotti RJ, Bertocchi GL, Lococo B, Albareda MC, De Rissio AM, Natale MA, Parodi C, Tarleton RL, Laucella SA.

Front Immunol. 2017 Sep 15;8:1141. doi: 10.3389/fimmu.2017.01141. eCollection 2017.

10.

Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi.

Weatherly DB, Peng D, Tarleton RL.

BMC Genomics. 2016 Sep 13;17(1):729. doi: 10.1186/s12864-016-3037-z.

11.

Chagas Disease: A Solvable Problem, Ignored.

Tarleton RL.

Trends Mol Med. 2016 Oct;22(10):835-838. doi: 10.1016/j.molmed.2016.07.008. Epub 2016 Aug 11.

12.

Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.

Rosenberg CS, Zhang W, Bustamante JM, Tarleton RL.

Infect Immun. 2016 Aug 19;84(9):2627-38. doi: 10.1128/IAI.00241-16. Print 2016 Sep.

13.

Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses.

Alvarez MG, Bertocchi GL, Cooley G, Albareda MC, Viotti R, Perez-Mazliah DE, Lococo B, Castro Eiro M, Laucella SA, Tarleton RL.

PLoS Negl Trop Dis. 2016 Apr 29;10(4):e0004657. doi: 10.1371/journal.pntd.0004657. eCollection 2016 Apr.

14.

A framework for ontology-based question answering with application to parasite immunology.

Asiaee AH, Minning T, Doshi P, Tarleton RL.

J Biomed Semantics. 2015 Jul 17;6:31. doi: 10.1186/s13326-015-0029-x. eCollection 2015.

15.

CD8+ T cells in Trypanosoma cruzi infection.

Tarleton RL.

Semin Immunopathol. 2015 May;37(3):233-8. doi: 10.1007/s00281-015-0481-9. Epub 2015 Apr 29. Review.

16.

Perturbed T cell IL-7 receptor signaling in chronic Chagas disease.

Albareda MC, Perez-Mazliah D, Natale MA, Castro-Eiro M, Alvarez MG, Viotti R, Bertocchi G, Lococo B, Tarleton RL, Laucella SA.

J Immunol. 2015 Apr 15;194(8):3883-9. doi: 10.4049/jimmunol.1402202. Epub 2015 Mar 13.

17.

Chemokine receptor 7 (CCR7)-expression and IFNγ production define vaccine-specific canine T-cell subsets.

Hartley AN, Tarleton RL.

Vet Immunol Immunopathol. 2015 Apr 15;164(3-4):127-36. doi: 10.1016/j.vetimm.2015.02.001. Epub 2015 Feb 7.

18.

CRISPR-Cas9-mediated single-gene and gene family disruption in Trypanosoma cruzi.

Peng D, Kurup SP, Yao PY, Minning TA, Tarleton RL.

MBio. 2014 Dec 30;6(1):e02097-14. doi: 10.1128/mBio.02097-14.

19.

Chagas disease and the london declaration on neglected tropical diseases.

Tarleton RL, Gürtler RE, Urbina JA, Ramsey J, Viotti R.

PLoS Negl Trop Dis. 2014 Oct 9;8(10):e3219. doi: 10.1371/journal.pntd.0003219. eCollection 2014 Oct. No abstract available.

20.
21.

Potential new clinical therapies for Chagas disease.

Bustamante JM, Tarleton RL.

Expert Rev Clin Pharmacol. 2014 May;7(3):317-25. doi: 10.1586/17512433.2014.909282. Epub 2014 Apr 9. Review.

PMID:
24716790
22.

Frequency of IFNγ-producing T cells correlates with seroreactivity and activated T cells during canine Trypanosoma cruzi infection.

Hartley AN, Cooley G, Gwyn S, Orozco MM, Tarleton RL.

Vet Res. 2014 Jan 23;45:6. doi: 10.1186/1297-9716-45-6.

23.

Polyfunctional T cell responses in children in early stages of chronic Trypanosoma cruzi infection contrast with monofunctional responses of long-term infected adults.

Albareda MC, De Rissio AM, Tomas G, Serjan A, Alvarez MG, Viotti R, Fichera LE, Esteva MI, Potente D, Armenti A, Tarleton RL, Laucella SA.

PLoS Negl Trop Dis. 2013 Dec 12;7(12):e2575. doi: 10.1371/journal.pntd.0002575. eCollection 2013.

24.
25.

Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence.

Galizzi M, Bustamante JM, Fang J, Miranda K, Soares Medeiros LC, Tarleton RL, Docampo R.

Mol Microbiol. 2013 Nov;90(4):699-715. doi: 10.1111/mmi.12392. Epub 2013 Sep 30.

26.

New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.

Bustamante JM, Craft JM, Crowe BD, Ketchie SA, Tarleton RL.

J Infect Dis. 2014 Jan 1;209(1):150-62. doi: 10.1093/infdis/jit420. Epub 2013 Aug 14.

27.

A systematic review of high quality diagnostic tests for Chagas disease.

Afonso AM, Ebell MH, Tarleton RL.

PLoS Negl Trop Dis. 2012;6(11):e1881. doi: 10.1371/journal.pntd.0001881. Epub 2012 Nov 8. Review.

28.

Is Chagas disease really the "new HIV/AIDS of the Americas"?

Tarleton RL, Curran JW.

PLoS Negl Trop Dis. 2012;6(10):e1861. doi: 10.1371/journal.pntd.0001861. Epub 2012 Oct 25. No abstract available.

29.

Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Perez-Mazliah DE, Alvarez MG, Cooley G, Lococo BE, Bertocchi G, Petti M, Albareda MC, Armenti AH, Tarleton RL, Laucella SA, Viotti R.

J Antimicrob Chemother. 2013 Feb;68(2):424-37. doi: 10.1093/jac/dks390. Epub 2012 Oct 26.

30.

Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA.

Bustamante JM, Park HJ, Tarleton RL; The Chagas Drug Discovery Consortium.

Expert Opin Drug Discov. 2011 Sep;6(9):965-73. doi: 10.1517/17460441.2011.602063. Epub 2011 Jul 19.

PMID:
22646217
31.

Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease.

Argüello RJ, Albareda MC, Alvarez MG, Bertocchi G, Armenti AH, Vigliano C, Meckert PC, Tarleton RL, Laucella SA.

PLoS One. 2012;7(5):e35966. doi: 10.1371/journal.pone.0035966. Epub 2012 May 4.

32.

Transgenic parasites accelerate drug discovery.

Rodriguez A, Tarleton RL.

Trends Parasitol. 2012 Mar;28(3):90-2. doi: 10.1016/j.pt.2011.12.003. Epub 2012 Jan 23.

33.

Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge.

Perez Brandan C, Padilla AM, Xu D, Tarleton RL, Basombrio MA.

PLoS Negl Trop Dis. 2011 Dec;5(12):e1418. doi: 10.1371/journal.pntd.0001418. Epub 2011 Dec 13.

34.

Methodological advances in drug discovery for Chagas disease.

Bustamante JM, Tarleton RL.

Expert Opin Drug Discov. 2011 Jun;6(6):653-661.

35.

Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Collins MH, Craft JM, Bustamante JM, Tarleton RL.

Infect Immun. 2011 Aug;79(8):3397-406. doi: 10.1128/IAI.01080-10. Epub 2011 May 31.

36.
37.

In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds.

Canavaci AM, Bustamante JM, Padilla AM, Perez Brandan CM, Simpson LJ, Xu D, Boehlke CL, Tarleton RL.

PLoS Negl Trop Dis. 2010 Jul 13;4(7):e740. doi: 10.1371/journal.pntd.0000740.

38.

CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.

Rosenberg CS, Martin DL, Tarleton RL.

J Immunol. 2010 Jul 1;185(1):560-8. doi: 10.4049/jimmunol.1000432. Epub 2010 Jun 7.

39.

Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling.

Martin DL, Murali-Krishna K, Tarleton RL.

Infect Immun. 2010 Jul;78(7):3154-9. doi: 10.1128/IAI.00275-10. Epub 2010 May 10.

40.

Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines.

Aponte JC, Vaisberg AJ, Castillo D, Gonzalez G, Estevez Y, Arevalo J, Quiliano M, Zimic M, Verástegui M, Málaga E, Gilman RH, Bustamante JM, Tarleton RL, Wang Y, Franzblau SG, Pauli GF, Sauvain M, Hammond GB.

Bioorg Med Chem. 2010 Apr 15;18(8):2880-6. doi: 10.1016/j.bmc.2010.03.018. Epub 2010 Mar 12.

PMID:
20356752
41.

Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina.

Olivera GC, Albareda MC, Alvarez MG, De Rissio AM, Fichera LE, Cooley G, Yachelini P, Hrellac HA, Riboldi H, Laucella SA, Tarleton RL, Postan M.

Microbes Infect. 2010 May;12(5):359-63. doi: 10.1016/j.micinf.2010.01.011. Epub 2010 Feb 1.

42.

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, Albareda MC, Lococo B, Postan M, Armenti A, Tarleton RL.

Clin Infect Dis. 2009 Dec 1;49(11):1675-84. doi: 10.1086/648072.

43.

Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence.

Albareda MC, Olivera GC, Laucella SA, Alvarez MG, Fernandez ER, Lococo B, Viotti R, Tarleton RL, Postan M.

J Immunol. 2009 Sep 15;183(6):4103-8. doi: 10.4049/jimmunol.0900852. Epub 2009 Aug 19.

44.

The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi.

Minning TA, Weatherly DB, Atwood J 3rd, Orlando R, Tarleton RL.

BMC Genomics. 2009 Aug 7;10:370. doi: 10.1186/1471-2164-10-370.

45.

CD8+ T cells in Trypanosoma cruzi infection.

Padilla AM, Bustamante JM, Tarleton RL.

Curr Opin Immunol. 2009 Aug;21(4):385-90. doi: 10.1016/j.coi.2009.07.006. Epub 2009 Jul 29. Review.

46.

Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection.

Padilla AM, Simpson LJ, Tarleton RL.

J Immunol. 2009 Jul 15;183(2):1245-52. doi: 10.4049/jimmunol.0901178. Epub 2009 Jun 24.

47.

Chromosome level assembly of the hybrid Trypanosoma cruzi genome.

Weatherly DB, Boehlke C, Tarleton RL.

BMC Genomics. 2009 Jun 1;10:255. doi: 10.1186/1471-2164-10-255.

48.

Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi.

Xu D, Brandán CP, Basombrío MA, Tarleton RL.

BMC Microbiol. 2009 May 11;9:90. doi: 10.1186/1471-2180-9-90.

49.

Eliminating Chagas disease: challenges and a roadmap.

Reithinger R, Tarleton RL, Urbina JA, Kitron U, Gürtler RE.

BMJ. 2009 Apr 14;338:b1283. doi: 10.1136/bmj.b1283. No abstract available.

50.

HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease.

Alvarez MG, Postan M, Weatherly DB, Albareda MC, Sidney J, Sette A, Olivera C, Armenti AH, Tarleton RL, Laucella SA.

PLoS Negl Trop Dis. 2008;2(9):e288. doi: 10.1371/journal.pntd.0000288. Epub 2008 Sep 3.

Supplemental Content

Loading ...
Support Center